Interleukin 2 signaling is required for CD4+ regulatory T cell function

被引:499
作者
Furtado, GC
de Lafaille, MAC
Kutchukhidze, N
Lafaille, JJ
机构
[1] NYU, Sch Med, Skirball Inst Biomol Med, Program Mol Pathognesis, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
关键词
CD4(+) T lymphocytes; immune tolerance; encephalomyelitis; autoimmunity; hypersensitivity;
D O I
10.1084/jem.20020190
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice deficient in interleukin (IL)-2 production or the IL-2 receptor α or β chains develop a lethal autoimmune syndrome. CD4+ regulatory T cells have been shown to prevent autoimmune diseases, allograft rejection, and to down-regulate antibody responses against foreign antigens. To assess the role of IL-2 in the generation and function of regulatory T cells, we transferred CD4+ T cells from mice genetically deficient in IL-2 or IL-2Rα (CD25) expression. A small number of splenic or thymic CD4+ T cells from IL-2 knockout mice can protect mice from spontaneous experimental autoimmune encephalomyelitis (EAE). In contrast, splenic or thymic CD4+ T cells from CD25 knockout donor mice conferred little or no protection. We conclude that T cells with regulatory potential can develop, undergo thymic selection, and migrate to the peripheral lymphoid organs in the absence of IL-2, and do not protect from disease by means of IL-2 secretion. However, IL-2 signaling in regulatory T cells is essential for their protective function. Altogether, our results favor a model whereby IL-2 induces regulatory T cell activity.
引用
收藏
页码:851 / 857
页数:7
相关论文
共 37 条
[1]   CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10 [J].
Annacker, O ;
Pimenta-Araujo, R ;
Burlen-Defranoux, O ;
Barbosa, TC ;
Cumano, A ;
Bandeira, A .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3008-3018
[2]   An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation [J].
Asseman, C ;
Mauze, S ;
Leach, MW ;
Coffman, RL ;
Powrie, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) :995-1003
[3]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[4]   REGULATION OF INTERLEUKIN-2 (IL 2) RECEPTOR EXPRESSION - IL 2 AS AN INDUCING SIGNAL FOR THE EXPRESSION OF ITS OWN RECEPTOR ON A MURINE T-HELPER CELL-LINE [J].
BISMUTH, G ;
MOREAU, JL ;
SOMME, G ;
DUPHOT, M ;
DAUTRYVARSAT, A ;
ROBB, RJ ;
THEZE, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1985, 15 (07) :723-727
[5]  
Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO
[6]  
2-H
[7]   Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma [J].
Chi, KH ;
Myers, JN ;
Chow, KC ;
Chan, WK ;
Tsang, YW ;
Chao, Y ;
Yen, SH .
ONCOLOGY, 2001, 60 (02) :110-115
[8]   Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes [J].
de Lafaille, MAC ;
Muriglan, S ;
Sunshine, MJ ;
Lei, Y ;
Kutchukhidze, N ;
Furtado, GC ;
Wensky, AK ;
Olivares-Villagómez, D ;
Lafaille, JJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (09) :1349-1359
[9]  
Furtado GD, 2001, IMMUNOL REV, V182, P122
[10]   Inducible IL-2 production by dendritic cells revealed by global gene expression analysis [J].
Granucci, F ;
Vizzardelli, C ;
Pavelka, N ;
Feau, S ;
Persico, M ;
Virzi, E ;
Rescigno, M ;
Moro, G ;
Ricciardi-Castagnoli, P .
NATURE IMMUNOLOGY, 2001, 2 (09) :882-888